 In the Q4 earnings release, Evelo Biosciences Inc NASDAQ: EVLO shared results from an ongoing Phase 1 single-center trial in healthy volunteers that showed that a capsule with an improved release profile could deliver EDP1815 higher up in the small intestine. 88 15 out of 17. 